Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop

When market conditions get choppy, pharmaceutical manufacturers usually float above the fray, but the second quarter of 2022 has certainly put the industry's standard stability to the test. The macroenvironment has delivered one volatile punch after another – inflation, supply constraints, labor shortages, rising US interest rates, a prolonged military conflict in Ukraine and a pandemic that continues to disrupt communities and business operations.

Amidst this turmoil, drug makers are poised to report second quarter sales and earnings, beginning with Johnson & Johnson on 19 July, and the world's biggest pharma companies are...